Team players in the pathogenesis of metabolic dysfunctions-associated steatotic liver disease: The basis of development of pharmacotherapy

doi:10.4291/wjgp.v15.i4.93606

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (13)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-9) series, Tables (1-2) series.

Item

Count

PDF

HTML

Figures (1-9)

Tables (1-2)

Sum=11

Aug 22, 2024 (publication date) through Aug 22, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pathophysiology

ISSN

2150-5330

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Pathophysiol. Aug 22, 2024; 15(4): 93606
Published online Aug 22, 2024. doi: 10.4291/wjgp.v15.i4.93606

Team players in the pathogenesis of metabolic dysfunctions-associated steatotic liver disease: The basis of development of pharmacotherapy

Shahid Habib

Shahid Habib, Department of Hepatology, Liver Institute PLLC, Tucson, AZ 85712, United States

Author contributions: Shahid H is responsible for hypothesis creation, data collection, critical data review and synthesis, manuscript writing and submission.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Shahid Habib, FCPS, MBBS, MRCP, Researcher, Department of Hepatology, Liver Institute PLLC, 2830 N Swan Road, Suite 180, Tucson, AZ 85712, United States. shabib@liverinstitutepllc.org

Received: March 1, 2024
Revised: May 14, 2024
Accepted: July 23, 2024
Published online: August 22, 2024
Processing time: 173 Days and 11.4 Hours

Core Tip

Core Tip: The pathogenesis of metabolic dysfunctions associated steatotic liver disease (MASLD) is complex and a thorough analysis of the contributing factors to disease progression is pivotal to individualized patient care. Understanding and identifying the key pathogenic processes responsible for MASLD in each patient allows for the utilization of appropriate and effective pharmacotherapy. This review details the various key players in MASLD pathogenesis, through the lens of carbohydrate and fat metabolism, to divulge new areas of focus that could strengthen the capability of precision medicine for this population of patients.